Table 1 Clinical characteristics (mean ± SD) and liver histology by baseline liver phenotype^a

Sex (male/female) (% males)

15/27 (36)

7/21 (25)

14/21 (40)

0.446

Age (years)

48.2 ± 8.7

47.1 ± 8.7

47.3 ± 8.5

0.910

Weight

128.7 ± 20.4

124.0 ± 15.7

134.4 ± 23.9

0.265

Weight at 12 mo

102.0 ± 20.0

91.1 ± 6.2

98.9 ± 19.8

0.200

BMI (kg/m²)

44.0 ± 6.4

43.9 ± 3.9

44.8 ± 6.9

0.824

BMI at 12 mo (kg/m²)

35.2 ± 6.4

32.1 ± 2.4

33.3 ± 5.7

0.289

Fasting glucose (mmol/L)

6.0 ± 0.8

6.5 ± 2.2

7.0 ± 2.4

0.287

Fasting glucose at 12 mo (mmol/L)

5.4 ± 0.7

5.4 ± 0.7

5.3 ± 0.5

0.581

Fasting insulin (mU/L)

13.9 ± 6.7

18.7 ± 10.7

39.9 ± 59.1

<0.001

Fasting insulin at 12 mo (mU/L)

8.6 ± 5.2

7.8 ± 3.9

11.3 ± 11.9

0.958

Diabetes (no/yes) (%)^c

32/10 (24)

18/10 (36)

18/16 (46)

0.105

Diabetes at 12 mo (no/yes) (%)^d

30/1 (2.4)

17/0 (0)

24/0 (0)

0.511

Cholesterol (mg/l)

4.2 ± 0.9

4.0 ± 0.7

4.7 ± 1.2

0.040

Cholesterol at 12 mo (mg/l)

4.2 ± 0.8

4.2 ± 0.8

4.7 ± 0.9

0.264

Triglycerides (mg/l)

1.5 ± 0.6

1.6 ± 0.7

1.8 ± 0.9

0.076

Triglycerides at 12 mo (mg/l)

1.0 ± 0.4

1.0 ± 0.3

1.2 ± 0.4

0.222

Plasma adiponectin (μg/ml)

3.6 ± 2.0

4.0 ± 2.1

2.8 ± 1.7

0.084

Plasma adiponectin at 12 mo (μg/ml)

13.0 ± 37.2

16.2 ± 43.3

5.4 ± 3.4

0.205

ALT (U/L)

40.0 ± 25.5

43.8 ± 17.9

58.2 ± 31.4

0.042

ALT at 12 mo (U/L)

27.4 ± 12.9

24.9 ± 12.9

27.8 ± 25.3

0.626

Steatosisgrade (n)

<0.001

 <5 %

42

0

0

 5–33 %

0

24

14

 33–66 %

0

2

14

 >66 %

0

2

7

Lobular Inflammation (n)

<0.001

 None

42

28

0

 <2 foci per 200*field

0

0

25

 2–4 foci per 200*field

0

0

10

Liver cell ballooning (n)

<0.001

 None

42

28

16

 Few balloon cells (n)

0

0

15

 Many cells/prominent ballooning

0

0

4

Fibrosis stage (n)

<0.001

 None

42

28

4

 Perisinusoidal or periportal

0

0

26

 Perisinusoidal and portan/periportal

0

0

22

 Bridging fibrosis

0

0

12

 Cirrhosis

0

0

1